AP

Amanda Park

Vice President, Business Development

Grace Therapeutics

Therapeutic Areas

Grace Therapeutics Pipeline

DrugIndicationPhase
GRC-101Rare Focal EpilepsyPhase 2
GRC-201Treatment-Resistant Focal Onset SeizuresPhase 1/2
GRC-301Neuropathic PainPreclinical